Wacker doubles production area at biologics plant
Wacker Chemie officially opens its new biologics plant in Jena, Germany.
The firm says the expansion will enable it to meet growing demand for biologically manufactured pharmaceuticals used to treat cancer, multiple sclerosis and hepatitis, among other indications.
The expansion, together with a building for process development and quality control completed last year, brings the total investment at the plant to Euro 18m.
Wacker has almost doubled the production area at the GMP-certified site. A new facility for product purification also allows up to three times higher product yields per batch.
"Demand for advanced biotech products is growing worldwide. Innovative, biotechnological processes such as Wacker's ESETEC secretion system allow us to meet demand and continue to shape the developments in biotechnology here in Germany," said Auguste Williams, a member of Wacker's Executive Board.
"We now have an ideal system for developing the sophisticated processes and analytical techniques of modern, microbe-based biologics," added Thomas Maier, managing director of Wacker Biotech.
"This allows Wacker to optimise the entire process chain, from lab operations to industrial GMP production. Customers thus benefit from a full process and analysis package provided from a single source. And with the expansion of our production capacities, we can now make our innovative ESETEC secretion technology available to more customers."
Traditional production methods aside, the focus of the new unit is on Wacker's ESETEC and DENSETEC proprietary technologies, which enable simpler, more cost-efficient and high-yield production of biologics for the pharmaceuticals industry.
You may also like
Finance
UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures
Read moreHeligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months